How to Buy Cyclacel Pharmaceuticals Stock
Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.
Cyclacel Pharmaceuticals stock last closed at $1.96, up 17.37% from the previous day, and has decreased 77.79% in one year. It has underperformed other stocks in the Biotechnology industry by 0.52 percentage points. Cyclacel Pharmaceuticals stock is currently +28.95% from its 52-week low of $1.52, and -85.15% from its 52-week high of $13.20.
At the moment, there are 1.32M shares of CYCC outstanding. The market capitalization of CYCC is $2.58M. In the last 24 hours, 113,657 CYCC shares were traded.
How to Buy Cyclacel Pharmaceuticals Stock
Wondering how to invest in Cyclacel Pharmaceuticals stock? Here's how.
- Decide where to buy Cyclacel Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you choose where to buy Cyclacel Pharmaceuticals stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Select your payment method and add your info.
- Research Cyclacel Pharmaceuticals stock: The Cyclacel Pharmaceuticals ticker symbol is CYCC. Is Cyclacel Pharmaceuticals stock a good investment? Should you buy shares of CYCC? How do CYCC's underlying business fundamentals look? Do top analysts think Cyclacel Pharmaceuticals is a good buy? Why has CYCC's stock price moved recently? (Hint: Our stock market research website can help you evaluate if CYCC is a good stock to buy).
- Execute your CYCC purchase: Decide if you will purchase CYCC shares at the current market price or use a limit order to purchase CYCC stock at a specific price.
- Get the latest news on your CYCC investment: Create a watchlist to key updates about your position in Cyclacel Pharmaceuticals stock.
Step 1: Decide where to buy Cyclacel Pharmaceuticals stock
You will need an online brokerage account in order to access the NASDAQ market and buy CYCC shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Industrials, New York to Shanghai — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal info so you can invest in CYCC stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open your new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have opened your account on the best stock trading app, you can securely and quickly fund your account:
Check out the video below for more details transferring funds into your investment account.
Step 4: Research Cyclacel Pharmaceuticals stock
After you have decided on the best place to buy Cyclacel Pharmaceuticals stock, it's very important to research their stock before you invest, so you actually wrap your head around the risk as well as the opportunity.
Cyclacel Pharmaceuticals stock data
Cyclacel Pharmaceuticals Fundamentals
WallStreetZen was created to help part-time investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on CYCC's stock page.
Is CYCC stock undervalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge CYCC's fair value.
Using relative valuations metrics:
- CYCC may be undervalued based on its P/B ratio of 4.26x, relative to Biotechnology industry P/B ratio of 5.83x
You can do additional valuation research on CYCC's stock here.
CYCC Financials at a glance
Pros:
- There are more short-term assets than long-term liabilities on the CYCC balance sheet.
Cons:
- CYCC has cash burn of 16118000. It does not have enough cash and short-term investments to cover this.
- CYCC has $3.38M in cash and short term investments. This is not sufficient to cover its annual cash burn of $16.12M.
- CYCC profit margin has gone down from N/A to -5,418.1% in the past year.
- CYCC has a relatively high debt to equity ratio of 13.51.
- There are more short-term liabilities than short-term assets on the CYCC balance sheet.
- Total CYCC debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy CYCC stock, according to Wall Street analysts?
Out of 1 Wall Street analysts who monitor CYCC, the consensus analyst rating on Cyclacel Pharmaceuticals is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Cyclacel Pharmaceuticals stock forecast page.
CYCC Technicals
CYCC Performance Metrics
Last year, CYCC revenue was $420.00k. During the last five year, CYCC's revenue has grown by 22.87% per year. This was slower than the Biotechnology industry average of 29.02%.
Find out more about CYCC's earnings and revenue performance here.
Latest Insiders Trades at CYCC
Over the past year, executives and large shareholders at CYCC have bought more shares than they have sold.
Paul McBarron, E. VP Fin CFO COO and Secretary of CYCC, was the latest CYCC insider to buy. They bought $6,252.09 worth of CYCC shares on Dec 21, 2023.
Learn more about who owns CYCC shares here.
Does CYCC provide a stable income stream?
No, Cyclacel Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your CYCC purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a given price limit, place a limit order.
Press the Open Trade button and eToro will place the order.
If you want more info about investing in stocks on eToro, click the how to video below:
Step 6: Get the latest news on your CYCC investment
Now that you own some CYCC shares, you'll want to stay up-to-date on your shares.
Start a watchlist to get notified of important updates regarding your CYCC stock.
CYCC Feed
How to Buy Stock in Cyclacel Pharmaceuticals
To summarize, here are the 6 steps for buying Cyclacel Pharmaceuticals stock:
- Decide where to buy Cyclacel Pharmaceuticals stock
- Sign up for a brokerage account
- Deposit money your investment account
- Research Cyclacel Pharmaceuticals stock
- Execute your CYCC purchase
- Get the latest news on your CYCC investment
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep tabs on your new investment in Cyclacel Pharmaceuticals, create a watchlist on WallStreetZen today.
More Articles You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.